BioCardia Competitors

BioCardia (NASDAQ:BCDA) and ADMA Biologics (NASDAQ:ADMA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for BioCardia and ADMA Biologics, as provided by MarketBeat.com.

BioCardia currently has a consensus target price of $9.25, indicating a potential upside of 168.90%. ADMA Biologics has a consensus target price of $7.80, indicating a potential upside of 350.87%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts plainly believe ADMA Biologics is more favorable than BioCardia.

Volatility and Risk

BioCardia has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500.

Profitability

This table compares BioCardia and ADMA Biologics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares BioCardia and ADMA Biologics' top-line revenue, earnings per share (EPS) and valuation.

BioCardia has higher earnings, but lower revenue than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

9.0% of BioCardia shares are owned by institutional investors. Comparatively, 48.9% of ADMA Biologics shares are owned by institutional investors. 40.9% of BioCardia shares are owned by company insiders. Comparatively, 11.7% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

ADMA Biologics beats BioCardia on 9 of the 14 factors compared between the two stocks.

CASI Pharmaceuticals (NASDAQ:CASI) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership.

Profitability

This table compares CASI Pharmaceuticals and BioCardia's net margins, return on equity and return on assets.

Institutional & Insider Ownership

32.0% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.0% of BioCardia shares are owned by institutional investors. 24.8% of CASI Pharmaceuticals shares are owned by company insiders. Comparatively, 40.9% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

CASI Pharmaceuticals has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for CASI Pharmaceuticals and BioCardia, as reported by MarketBeat.com.

CASI Pharmaceuticals currently has a consensus price target of $4.20, suggesting a potential upside of 191.67%. BioCardia has a consensus price target of $9.25, suggesting a potential upside of 168.90%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe CASI Pharmaceuticals is more favorable than BioCardia.

Earnings & Valuation

This table compares CASI Pharmaceuticals and BioCardia's revenue, earnings per share (EPS) and valuation.

BioCardia has lower revenue, but higher earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Summary

CASI Pharmaceuticals beats BioCardia on 9 of the 14 factors compared between the two stocks.

BioCardia (NASDAQ:BCDA) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, earnings and analyst recommendations.

Insider and Institutional Ownership

9.0% of BioCardia shares are owned by institutional investors. Comparatively, 0.4% of Genfit shares are owned by institutional investors. 40.9% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for BioCardia and Genfit, as provided by MarketBeat.com.

BioCardia currently has a consensus price target of $9.25, suggesting a potential upside of 168.90%. Genfit has a consensus price target of $51.00, suggesting a potential upside of 1,143.90%. Given Genfit's higher possible upside, analysts clearly believe Genfit is more favorable than BioCardia.

Risk & Volatility

BioCardia has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500. Comparatively, Genfit has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Earnings & Valuation

This table compares BioCardia and Genfit's top-line revenue, earnings per share and valuation.

BioCardia has higher earnings, but lower revenue than Genfit. Genfit is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BioCardia and Genfit's net margins, return on equity and return on assets.

BioCardia (NASDAQ:BCDA) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Profitability

This table compares BioCardia and X4 Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations for BioCardia and X4 Pharmaceuticals, as reported by MarketBeat.

BioCardia currently has a consensus price target of $9.25, suggesting a potential upside of 168.90%. X4 Pharmaceuticals has a consensus price target of $18.00, suggesting a potential upside of 140.32%. Given BioCardia's higher possible upside, equities research analysts plainly believe BioCardia is more favorable than X4 Pharmaceuticals.

Insider & Institutional Ownership

9.0% of BioCardia shares are owned by institutional investors. Comparatively, 67.8% of X4 Pharmaceuticals shares are owned by institutional investors. 40.9% of BioCardia shares are owned by company insiders. Comparatively, 4.9% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares BioCardia and X4 Pharmaceuticals' gross revenue, earnings per share and valuation.

BioCardia has higher revenue and earnings than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

BioCardia has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

Summary

BioCardia beats X4 Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Voyager Therapeutics (NASDAQ:VYGR) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Insider & Institutional Ownership

78.8% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 9.0% of BioCardia shares are owned by institutional investors. 23.9% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 40.9% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Voyager Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Voyager Therapeutics and BioCardia, as reported by MarketBeat.

Voyager Therapeutics presently has a consensus price target of $10.55, suggesting a potential upside of 132.38%. BioCardia has a consensus price target of $9.25, suggesting a potential upside of 168.90%. Given BioCardia's stronger consensus rating and higher possible upside, analysts clearly believe BioCardia is more favorable than Voyager Therapeutics.

Profitability

This table compares Voyager Therapeutics and BioCardia's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Voyager Therapeutics and BioCardia's top-line revenue, earnings per share and valuation.

BioCardia has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Summary

BioCardia beats Voyager Therapeutics on 7 of the 13 factors compared between the two stocks.

Fennec Pharmaceuticals (NASDAQ:FENC) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, earnings, risk and institutional ownership.

Earnings and Valuation

This table compares Fennec Pharmaceuticals and BioCardia's revenue, earnings per share and valuation.

Fennec Pharmaceuticals has higher earnings, but lower revenue than BioCardia. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Fennec Pharmaceuticals and BioCardia's net margins, return on equity and return on assets.

Insider and Institutional Ownership

53.6% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 9.0% of BioCardia shares are held by institutional investors. 9.1% of Fennec Pharmaceuticals shares are held by insiders. Comparatively, 40.9% of BioCardia shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations and price targets for Fennec Pharmaceuticals and BioCardia, as provided by MarketBeat.

Fennec Pharmaceuticals presently has a consensus target price of $14.50, suggesting a potential upside of 129.43%. BioCardia has a consensus target price of $9.25, suggesting a potential upside of 168.90%. Given BioCardia's higher probable upside, analysts plainly believe BioCardia is more favorable than Fennec Pharmaceuticals.

Volatility & Risk

Fennec Pharmaceuticals has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500.

Summary

Fennec Pharmaceuticals beats BioCardia on 8 of the 13 factors compared between the two stocks.